Nowarta110

Small molecule

NNowarta Biopharma Inc

Nowarta110 is one of 13 small molecule programs targeting Plantar Wart. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plantar WartActive, not recruiting

Plantar WartPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Plantar Wart

#DrugCompanyPhaseTrials

Aldara

BBausch Health Americas, Inc.

Approved

1 2

Zovirax

BBp Consulting, Inc

Approved

1 3

CRYOTHERAPY

AAssistance Publique - Hôpitaux de Paris

Approved

1 4

Salicylate

AAssistance Publique - Hôpitaux de Paris

Approved

1 5

Inomax

MMallinckrodt

Phase 2

1 6

Salicylic Acid

HHadassah Medical Organization

Phase 3

1 7

Blenoxane

Bristol-Myers Squibb

Preclinical

3 8

Potassium Hydroxide

SSohag University

Phase 3

1 9

Intralesional Acyclovir

RRiphah International University

Phase 3

1 10

Adrucil

EElorac, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Plantar Wart1 trial

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Completed·NNowarta Biopharma Inc·Phase 1/2·NCT02338336·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nowarta110. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nowarta110 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nowarta110. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nowarta Biopharma Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNowarta Biopharma Inc

Nowarta110

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Plantar Wart1 trial

References

Drug Info

Quick Facts

Related News